Filing Flows › Syndax Pharmaceuticals (SNDX) › Q1 2026
Syndax Pharmaceuticals (SNDX) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Syndax Pharmaceuticals (SNDX) reported revenue of $64.9M for the first quarter 2026 (Q1 2026), +224% from a year earlier and -6% from the quarter before. Operating margin was -52.7%, net loss $42.7M (65.8% of revenue).
Syndax Pharmaceuticals, Q1 2026: revenue $64.9M (+224% year over year), operating margin -52.7%, net loss $42.7M, operating cash flow −$50.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $64.9M | -6% | +224% |
| Operating profit | −$34.2M | — | — |
| Net earnings | −$42.7M | — | — |
| Operating cash flow | −$50.3M | — | — |
What changed
Revenue was $64.9M in Q1 2026, up 224% year over year and down 6% from the previous quarter. Product was the largest line at 75% of revenue. Product added $28.9M year over year (up 144%), 64% of the total change.
Operating costs exceeded revenue by $34.2M, an operating margin of -52.7%. Total costs fell 5% while revenue rose 224%. The fastest-growing cost line was Other operating costs (+133%). The quarter ended with a net loss of $42.7M, narrower than the previous quarter's $68.0M loss.
Operating cash flow was −$50.3M. Non-cash charges added back $4.0M of depreciation and $12.1M of share-based compensation. Working capital and other items used $23.7M.
Questions
What was Syndax Pharmaceuticals' revenue in the first quarter 2026?
Syndax Pharmaceuticals (SNDX) reported revenue of $64.9M for the first quarter 2026 (Q1 2026), +224% from a year earlier and -6% from the quarter before.
Was Syndax Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $34.2M (-52.7% of revenue) and net loss $42.7M.